THE SAFETY AND EFFICACY OF RIFAPENTINE USED TO TREAT DRUG-SUSCEPTIBLE PULMONARY TUBERCULOSIS
A comparative investigation was conducted to study the safety and efficacy of rifapentine (Rifapex, Lipin Ltd, India) used to treat 65 patients with drug-susceptible pulmonary tuberculosis. A study group of 41 patients took rifapentine thrice weekly; a comparison group of 24 patients received a stan...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
New Terra Publishing House
2014-04-01
|
| Series: | Туберкулез и болезни лёгких |
| Subjects: | |
| Online Access: | https://www.tibl-journal.com/jour/article/view/64 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850222972116140032 |
|---|---|
| author | N. V. Litvinova T. N. Ivanushkina L. V. Slogotskaya D. A. Ivanova S. E. Borisov |
| author_facet | N. V. Litvinova T. N. Ivanushkina L. V. Slogotskaya D. A. Ivanova S. E. Borisov |
| author_sort | N. V. Litvinova |
| collection | DOAJ |
| description | A comparative investigation was conducted to study the safety and efficacy of rifapentine (Rifapex, Lipin Ltd, India) used to treat 65 patients with drug-susceptible pulmonary tuberculosis. A study group of 41 patients took rifapentine thrice weekly; a comparison group of 24 patients received a standard thrice-weekly regimen of rifampicin according to the manufacturer’s guidelines. The follow-up lasted 12 weeks. The rates of adverse reactions during treatment with rifapentine and rifampicin were 63.4 and 70.8%, respectively (the differences were statistically insignificant). A drug was discontinued because of side effects in 2 (4.9%) and 5 (20.8%) patients in the study and comparison groups, respectively (p = 0.09, Fisher’s exact test). Therapeutic effectiveness was comparable in both groups: all the patients ceased to excrete bacteria, had none complaints or symptoms of intoxication, showed pronounced X-ray changes as reductions in infiltrative changes, consolidation, and foci (the effectiveness was analyzed in 35 patients (20 from the study group and 15 from the comparison one). The findings (comparable efficacy and tolerability, the lower rate of unremovable adverse reactions associated with rifapentine than that with rifampicin) provide a basis for using rifapentine in patients with drug-susceptible tuberculosis. |
| format | Article |
| id | doaj-art-c1575896b0b34072b3cfb34ea93c2128 |
| institution | OA Journals |
| issn | 2075-1230 2542-1506 |
| language | Russian |
| publishDate | 2014-04-01 |
| publisher | New Terra Publishing House |
| record_format | Article |
| series | Туберкулез и болезни лёгких |
| spelling | doaj-art-c1575896b0b34072b3cfb34ea93c21282025-08-20T02:06:07ZrusNew Terra Publishing HouseТуберкулез и болезни лёгких2075-12302542-15062014-04-0104465364THE SAFETY AND EFFICACY OF RIFAPENTINE USED TO TREAT DRUG-SUSCEPTIBLE PULMONARY TUBERCULOSISN. V. Litvinova0T. N. Ivanushkina1L. V. Slogotskaya2D. A. Ivanova3S. E. Borisov4ГКУЗ «Московский городской научно-практический центр борьбы с туберкулезом» Департамента здравоохранения города МосквыГКУЗ «Московский городской научно-практический центр борьбы с туберкулезом» Департамента здравоохранения города МосквыГКУЗ «Московский городской научно-практический центр борьбы с туберкулезом» Департамента здравоохранения города МосквыГКУЗ «Московский городской научно-практический центр борьбы с туберкулезом» Департамента здравоохранения города МосквыГКУЗ «Московский городской научно-практический центр борьбы с туберкулезом» Департамента здравоохранения города МосквыA comparative investigation was conducted to study the safety and efficacy of rifapentine (Rifapex, Lipin Ltd, India) used to treat 65 patients with drug-susceptible pulmonary tuberculosis. A study group of 41 patients took rifapentine thrice weekly; a comparison group of 24 patients received a standard thrice-weekly regimen of rifampicin according to the manufacturer’s guidelines. The follow-up lasted 12 weeks. The rates of adverse reactions during treatment with rifapentine and rifampicin were 63.4 and 70.8%, respectively (the differences were statistically insignificant). A drug was discontinued because of side effects in 2 (4.9%) and 5 (20.8%) patients in the study and comparison groups, respectively (p = 0.09, Fisher’s exact test). Therapeutic effectiveness was comparable in both groups: all the patients ceased to excrete bacteria, had none complaints or symptoms of intoxication, showed pronounced X-ray changes as reductions in infiltrative changes, consolidation, and foci (the effectiveness was analyzed in 35 patients (20 from the study group and 15 from the comparison one). The findings (comparable efficacy and tolerability, the lower rate of unremovable adverse reactions associated with rifapentine than that with rifampicin) provide a basis for using rifapentine in patients with drug-susceptible tuberculosis.https://www.tibl-journal.com/jour/article/view/64rifapentinedrug susceptibility in mycobacterium tuberculosisadverse reactions |
| spellingShingle | N. V. Litvinova T. N. Ivanushkina L. V. Slogotskaya D. A. Ivanova S. E. Borisov THE SAFETY AND EFFICACY OF RIFAPENTINE USED TO TREAT DRUG-SUSCEPTIBLE PULMONARY TUBERCULOSIS Туберкулез и болезни лёгких rifapentine drug susceptibility in mycobacterium tuberculosis adverse reactions |
| title | THE SAFETY AND EFFICACY OF RIFAPENTINE USED TO TREAT DRUG-SUSCEPTIBLE PULMONARY TUBERCULOSIS |
| title_full | THE SAFETY AND EFFICACY OF RIFAPENTINE USED TO TREAT DRUG-SUSCEPTIBLE PULMONARY TUBERCULOSIS |
| title_fullStr | THE SAFETY AND EFFICACY OF RIFAPENTINE USED TO TREAT DRUG-SUSCEPTIBLE PULMONARY TUBERCULOSIS |
| title_full_unstemmed | THE SAFETY AND EFFICACY OF RIFAPENTINE USED TO TREAT DRUG-SUSCEPTIBLE PULMONARY TUBERCULOSIS |
| title_short | THE SAFETY AND EFFICACY OF RIFAPENTINE USED TO TREAT DRUG-SUSCEPTIBLE PULMONARY TUBERCULOSIS |
| title_sort | safety and efficacy of rifapentine used to treat drug susceptible pulmonary tuberculosis |
| topic | rifapentine drug susceptibility in mycobacterium tuberculosis adverse reactions |
| url | https://www.tibl-journal.com/jour/article/view/64 |
| work_keys_str_mv | AT nvlitvinova thesafetyandefficacyofrifapentineusedtotreatdrugsusceptiblepulmonarytuberculosis AT tnivanushkina thesafetyandefficacyofrifapentineusedtotreatdrugsusceptiblepulmonarytuberculosis AT lvslogotskaya thesafetyandefficacyofrifapentineusedtotreatdrugsusceptiblepulmonarytuberculosis AT daivanova thesafetyandefficacyofrifapentineusedtotreatdrugsusceptiblepulmonarytuberculosis AT seborisov thesafetyandefficacyofrifapentineusedtotreatdrugsusceptiblepulmonarytuberculosis AT nvlitvinova safetyandefficacyofrifapentineusedtotreatdrugsusceptiblepulmonarytuberculosis AT tnivanushkina safetyandefficacyofrifapentineusedtotreatdrugsusceptiblepulmonarytuberculosis AT lvslogotskaya safetyandefficacyofrifapentineusedtotreatdrugsusceptiblepulmonarytuberculosis AT daivanova safetyandefficacyofrifapentineusedtotreatdrugsusceptiblepulmonarytuberculosis AT seborisov safetyandefficacyofrifapentineusedtotreatdrugsusceptiblepulmonarytuberculosis |